Business
Bausch Health Announces Fourth Quarter and Full-Year 2024 Results
Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAA...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"Bausch Health Announces Fourth Quarter and Full-Year 2024 ResultsSeventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidanceFourth Quarter Consolidated Revenues of $2.56 billion, up 6% on a Reported basis and up 9% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of $9.63 billion, up 10% on a Reported basis and 8% on an Organic (non-GAAP)1 basis, with growth in all segmentsGAAP Net Income Attributable to Bausch Health Companies Inc. of $93 million for the quarter and GAAP Net Loss of $46 million for the yearConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $935 million for the quarter, up 8%, and $3.31 billion for the year, up 10% LAVAL, QC / ACCESS Newswire / February 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (\"Bausch Health\" the \"Company,\" \"we\" or \"our\") today announced its fourth quarter and full-year 2024 financial results and other key updates for the quarter.\"2024 was a year of delivering on our commitments, where we achieved the high-end of our revenue guidance range, and exceeded our adjusted EBITDA excluding Bausch + Lomb, and adjusted operating cash flow guidance expectations. We generated growth across all our business segments, highlighting the broad strength of our diverse portfolio that is supported by our strategic investments in the business. We also made progress on key initiatives, positioning us well to carry our momentum into 2025 as we pursue additional opportunities to deliver innovative solutions for patients.\" said Thomas J. Appio, Chief Executive Officer, Bausch Health.Fourth Quarter and Full-Year 2024 Revenue PerformanceTotal consolidated reported revenues were $2.56 billion for the fourth quarter of 2024, compared with $2.41 billion in the fourth quarter of 2023, an increase of $151 million, or 6%. Excluding the impact of foreign exchange of $28 million, acquisitions of $5 million, and divestitures and discontinuations of $29 million, revenue increased by 9% on an organic1 basis compared with the fourth quarter of 2023.Total consolidated reported revenues were $9.63 billion for the full year of 2024, compared with $8.76 billion for the full year of 2023, an increase of $868 million, or 10%....